- Home
- GMAB vs ACI Comparison
GMAB vs ACI Comparison
Compare GMAB & ACI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GMAB
- ACI
- Stock Information
- Founded
- GMAB 1999
- ACI 1860
- Country
- GMAB Denmark
- ACI United States
- Employees
- GMAB N/A
- ACI N/A
- Industry
- GMAB Biotechnology: Pharmaceutical Preparations
- ACI Food Chains
- Sector
- GMAB Health Care
- ACI Consumer Staples
- Exchange
- GMAB Nasdaq
- ACI Nasdaq
- Market Cap
- GMAB 13.7B
- ACI 12.8B
- IPO Year
- GMAB N/A
- ACI 2020
- Fundamental
- Price
- GMAB $21.88
- ACI $20.48
- Analyst Decision
- GMAB Buy
- ACI Buy
- Analyst Count
- GMAB 7
- ACI 13
- Target Price
- GMAB $37.80
- ACI $24.38
- AVG Volume (30 Days)
- GMAB 1.5M
- ACI 6.8M
- Earning Date
- GMAB 08-07-2025
- ACI 07-15-2025
- Dividend Yield
- GMAB N/A
- ACI 2.92%
- EPS Growth
- GMAB 276.80
- ACI N/A
- EPS
- GMAB 18.36
- ACI 1.64
- Revenue
- GMAB $3,230,902,140.00
- ACI $81,006,300,000.00
- Revenue This Year
- GMAB $747.74
- ACI $4.47
- Revenue Next Year
- GMAB $14.81
- ACI $0.66
- P/E Ratio
- GMAB $1.19
- ACI $12.52
- Revenue Growth
- GMAB 25.43
- ACI 1.46
- 52 Week Low
- GMAB $17.24
- ACI $17.00
- 52 Week High
- GMAB $28.56
- ACI $23.20
- Technical
- Relative Strength Index (RSI)
- GMAB 56.89
- ACI 37.16
- Support Level
- GMAB $21.10
- ACI $22.06
- Resistance Level
- GMAB $21.90
- ACI $22.39
- Average True Range (ATR)
- GMAB 0.39
- ACI 0.49
- MACD
- GMAB 0.11
- ACI -0.19
- Stochastic Oscillator
- GMAB 79.95
- ACI 12.85
About GMAB Genmab A/S ADS
Genmab is a Copenhagen-based biotechnology company specializing in antibody therapeutics for the treatment of cancer. Genmab's proprietary antibody technologies are DuoBody, HexaBody, DuoHexaBody, and HexElect. Johnson & Johnson partnered with Genmab to create Darzalex, which is regarded as the standard of care for multiple myeloma and is Genmab's leading product. Genmab also has Tepezza for thyroid eye disease (partnered with Horizon), Kesimpta for relapsing multiple sclerosis (partnered with Novartis), Rybrevant (partnered with Johnson & Johnson) for non-small cell lung cancer (NSCLC), Tivdak (partnered with Seagen) for cervical cancer, and Epkinly (partnered with AbbVie) for diffuse large B-cell lymphoma. Genmab has several pipeline candidates targeting other oncologic indications.
About ACI Albertsons Companies Inc.
Albertsons is the second-largest supermarket operator in the United States with about 2,300 stores across a variety of banners. Around 80% of the firm's sales comes from nonperishable and fresh food, of which 25% comes from its portfolio of private brands. The company operates fuel centers at about 20% of its store locations and pharmacies at 75%. Albertsons went public in 2020 following years of ownership under private equity firm Cerberus Capital Management, which still owns about a fourth of the outstanding shares.